T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma.


Journal

Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435

Informations de publication

Date de publication:
02 2019
Historique:
received: 18 06 2018
accepted: 19 09 2018
pubmed: 22 9 2018
medline: 6 5 2020
entrez: 22 9 2018
Statut: ppublish

Résumé

Primary testicular lymphoma is a rare lymphoid malignancy, most often, histologically, representing diffuse large B-cell lymphoma. The tumor microenvironment and limited immune surveillance have a major impact on diffuse large B-cell lymphoma pathogenesis and survival, but the impact on primary testicular lymphoma is unknown. Here, the purpose of the study was to characterize the tumor microenvironment in primary testicular lymphoma, and associate the findings with outcome. We profiled the expression of 730 immune response genes in 60 primary testicular lymphomas utilizing the Nanostring platform, and used multiplex immunohistochemistry to characterize the immune cell phenotypes in the tumor tissue. We identified a gene signature enriched for T-lymphocyte markers differentially expressed between the patients. Low expression of the signature predicted poor outcome independently of the International Prognostic Index (progression-free survival: HR=2.810, 95%CI: 1.228-6.431,

Identifiants

pubmed: 30237271
pii: haematol.2018.200105
doi: 10.3324/haematol.2018.200105
pmc: PMC6355505
doi:

Substances chimiques

Biomarkers 0
Biomarkers, Tumor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

338-346

Informations de copyright

Copyright © 2019 Ferrata Storti Foundation.

Références

Oncogene. 2015 Sep 3;34(36):4673-82
pubmed: 25639873
Clin Cancer Res. 2017 Jun 15;23(12):3203-3213
pubmed: 28302866
Nat Rev Clin Oncol. 2018 Jan;15(1):31-46
pubmed: 28857075
Cancer Immunol Immunother. 2017 Oct;66(10):1295-1306
pubmed: 28555258
Sci Rep. 2017 Nov 14;7(1):15580
pubmed: 29138507
Oncoimmunology. 2017 Mar 3;6(4):e1295202
pubmed: 28507804
Blood. 2016 Mar 17;127(11):1410-6
pubmed: 26755709
Blood. 2004 Jun 1;103(11):4251-8
pubmed: 14976040
Cancer Discov. 2017 Jan;7(1):38-53
pubmed: 27733359
Leukemia. 2016 Feb;30(2):361-72
pubmed: 26308769
Blood. 2000 Nov 15;96(10):3569-77
pubmed: 11071656
Blood. 2014 Jan 23;123(4):486-93
pubmed: 24282217
J Pathol. 2005 Jul;206(3):328-36
pubmed: 15887291
Nature. 2011 Jul 27;476(7360):298-303
pubmed: 21796119
Cancer Cell. 2011 Dec 13;20(6):728-40
pubmed: 22137796
J Clin Oncol. 2001 Feb 1;19(3):720-6
pubmed: 11157023
Lancet Haematol. 2015 Oct;2(10):e445-55
pubmed: 26686046
Haematologica. 2018 Nov;103(11):1908-1914
pubmed: 30026337
Blood. 2010 Aug 12;116(6):926-34
pubmed: 20439625
Clin Cancer Res. 2006 May 1;12(9):2698-705
pubmed: 16675561
Am J Hematol. 2013 Apr;88(4):273-6
pubmed: 23460351
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
Cancer Cell. 2015 Dec 14;28(6):690-714
pubmed: 26678337
Leuk Res. 2015 Oct;39(10):1006-19
pubmed: 26298174
Cancer Immunol Res. 2016 Jul;4(7):563-8
pubmed: 27197067
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
Nat Rev Cancer. 2014 Aug;14(8):517-34
pubmed: 25008267
J Clin Oncol. 2016 Apr 1;34(10):1104-11
pubmed: 26884582
Immunology. 2013 Oct;140(2):259-72
pubmed: 23789844
Biochim Biophys Acta. 2016 Mar;1863(3):471-482
pubmed: 26554850
Nat Rev Clin Oncol. 2017 Apr;14(4):203-220
pubmed: 27805626
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Nat Immunol. 2013 Oct;14(10):1014-22
pubmed: 24048123
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
Blood. 2004 Jan 1;103(1):275-82
pubmed: 14504078
Blood. 2009 Apr 16;113(16):3809-12
pubmed: 19196657
Transl Cancer Res. 2017 Feb;6(1):93-103
pubmed: 28955654
Genome Biol. 2006;7(10):R100
pubmed: 17076895

Auteurs

Suvi-Katri Leivonen (SK)

Research Program Unit, Medical Faculty, University of Helsinki, Finland.
Department of Oncology, Comprehensive Cancer Center, Helsinki University Hospital, Finland.

Marjukka Pollari (M)

Research Program Unit, Medical Faculty, University of Helsinki, Finland.
Department of Oncology, Tampere University Hospital, Finland.

Oscar Brück (O)

Hematology Research Unit Helsinki, Department of Clinical Chemistry and Hematology, University of Helsinki, Finland.

Teijo Pellinen (T)

Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland.

Matias Autio (M)

Research Program Unit, Medical Faculty, University of Helsinki, Finland.
Department of Oncology, Comprehensive Cancer Center, Helsinki University Hospital, Finland.

Marja-Liisa Karjalainen-Lindsberg (ML)

Department of Pathology, Helsinki University Hospital, Finland.

Susanna Mannisto (S)

Research Program Unit, Medical Faculty, University of Helsinki, Finland.
Department of Oncology, Comprehensive Cancer Center, Helsinki University Hospital, Finland.

Pirkko-Liisa Kellokumpu-Lehtinen (PL)

Department of Oncology, Tampere University Hospital, Finland.
University of Tampere, Faculty of Medicine and Life Sciences, Finland.

Olli Kallioniemi (O)

Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland.
Science for Life Laboratory, Karolinska Institutet, Department of Oncology and Pathology, Solna, Sweden.

Satu Mustjoki (S)

Hematology Research Unit Helsinki, Department of Clinical Chemistry and Hematology, University of Helsinki, Finland.
Department of Hematology, Comprehensive Cancer Center, Helsinki University Hospital, Finland.

Sirpa Leppä (S)

Research Program Unit, Medical Faculty, University of Helsinki, Finland sirpa.leppa@helsinki.fi.
Department of Oncology, Comprehensive Cancer Center, Helsinki University Hospital, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH